Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

S2473

Varithena versus endothermal ablation of the great saphenous vein (veritas)
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT05312970
Great Saphenous Vein Incompetence
Source :Importé depuis le centre
Varicose Veins
Recrutement fermé
Dernière modification : 2026/03/19
Type de recherche

Interventionnel

Médicament expérimental

PHASE4


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Varicose Veins

Source : Importé depuis le centre

Profil des participants

Limites d'âge
minimum : 18 ans
Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Age ≥ 18
* Primary GSV incompetence, defined as reflux \> 0.5 seconds on Duplex ultrasound in a single limb (Note the contralateral limb can have varicosities or SVI if intervention is not required within 3 months i.e. asymptomatic)
* Failed conservative therapy (compression, diet, exercise, leg elevation)
* CEAP Clinical Condition Classification C2 - C6
* Vein diameter 5-10mm, inclusive
* GSV treatable length \> 10cm
* Superficial venous disease manifest by clinical symptoms (rVCSS ≥ 4)
* Able to comprehend and sign an informed consent document and complete written study questionnaires
* Willing and able to return for scheduled follow-up visits (7-days, 3-months, 6-months, 12-months, 24-months, and 36-months post-procedure)
* Willingness to comply with post-treatment compression protocol

Exclusion Criteria:

* Allergy to polidocanol, xylocaine, or epinephrine
* Deep vein thrombosis or pulmonary embolism within 3 months prior to randomization or hypercoagulable disorder
* Post thrombotic deep vein disease above the calf veins
* Pregnancy or lactating (within 30 days of randomization)
* Symptomatic peripheral arterial disease or ankle-brachial pressure index (ABPI) \< 0.8
* Previous treatment to targeted incompetent GSV or previous superficial thrombophlebitis in targeted GSV
* Previous venous intervention in affected limb in past 3 months
* Local aneurysmal GSV segments
* Inability to walk unaided
* Inability to wear post-procedure compression bandaging and stockings
* Patients with clinically significant reflux of the small saphenous vein (SSV) or anterior accessory saphenous vein (AASV)
* In the clinical judgement of the investigator, patient who will require ipsilateral deep venous intervention within 3 months following randomized treatment
* In the clinical judgement of the investigator, patient who will require contralateral venous intervention (superficial or deep) within 3 months following randomized treatment
* Patient on therapeutic anticoagulants
* Active malignancy
* Life expectancy \< 2 years
* Documented COVID-19 infection currently or within 2 months prior to randomization
* Enrollment in another clinical trial that could confound the endpoint within 3 months prior to screening or within 3 months following enrollment

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Varithena® Varithena® (polidocanol injectable foam) 1% Donnée non disponible
  • Inconnu
  • FDA-approved ETA systems FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems. Donnée non disponible
  • Inconnu
  • Varithena®
    État du recrutement
    unknown
    FDA-approved ETA systems
    État du recrutement
    unknown
    Données à jour depuis : 19 mars 2026

    Description de l'étude

    Résumé de l'étude

    The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.

    Source : Importé depuis le centre

    To collect comparative evidence on patient reported outcomes of Varithena compared to ETA when used to treat the incompetent great saphenous vein (GSV). ETA will include either radiofrequency ablation or endovenous laser ablation according to the site's standard practice. To provide long term (1-year, 2-year, and 3-year) outcomes.

    Source : Importé depuis le centre

    Sites

    Centres participants

      9 centres
    • CARDIOVASCULAR INSTITUTE OF THE SOUTH

      Houma

      LOUISIANA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • ENGLEWOOD HOSPITAL AND MEDICAL CENTER

      Englewood

      NEW JERSEY, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • LAKE WASHINGTON VASCULAR, LLC

      Bellevue

      WASHINGTON, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • MEDSTAR GEORGETOWN UNIVERSITY HOSPITAL (LOMBARDI COMPREHENSIVE CANCER CENTER)

      Washington d.c.

      DISTRICT OF COLUMBIA, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • NEW YORK PRESBYTERIAN HOSPITAL/COLUMBIA UNIVERSITY MEDICAL CENTER

      New york

      NEW YORK, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • STONY BROOK UNIVERSITY HOSPITAL/ STONY BROOK CHILDREN'S

      Stony brook

      NEW YORK, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • UT PHYSICIANS CARDIOTHORACIC AND VASCULAR SURGERY

      Houston

      TEXAS, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • VASCULAR CARE CONNECTICUT

      Darien

      CONNECTICUT, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ
    • VEIN HEALTHCARE CENTER

      South portland

      MAINE, UNITED STATES

      Recrutement local
      État du recrutement: FERMÉ

    Dernière modification : 19 mars 2026
    Données à jour depuis : 21 mars
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT05312970